Logo image of ENSC

ENSYSCE BIOSCIENCES INC (ENSC) Stock Fundamental Analysis

NASDAQ:ENSC - Nasdaq - US2936025046 - Common Stock - Currency: USD

3.1201  -0.55 (-14.98%)

Fundamental Rating

3

ENSC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. ENSC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ENSC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ENSC had negative earnings in the past year.
In the past year ENSC has reported a negative cash flow from operations.
ENSC had negative earnings in 4 of the past 5 years.
In the past 5 years ENSC always reported negative operating cash flow.
ENSC Yearly Net Income VS EBIT VS OCF VS FCFENSC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

ENSC's Return On Assets of -142.70% is on the low side compared to the rest of the industry. ENSC is outperformed by 83.98% of its industry peers.
Looking at the Return On Equity, with a value of -215.38%, ENSC is doing worse than 70.42% of the companies in the same industry.
Industry RankSector Rank
ROA -142.7%
ROE -215.38%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENSC Yearly ROA, ROE, ROICENSC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K 15K

1.3 Margins

ENSC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENSC Yearly Profit, Operating, Gross MarginsENSC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

There is no outstanding debt for ENSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ENSC Yearly Shares OutstandingENSC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
ENSC Yearly Total Debt VS Total AssetsENSC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

ENSC has an Altman-Z score of -32.85. This is a bad value and indicates that ENSC is not financially healthy and even has some risk of bankruptcy.
ENSC has a Altman-Z score of -32.85. This is amonst the worse of the industry: ENSC underperforms 90.85% of its industry peers.
There is no outstanding debt for ENSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.85
ROIC/WACCN/A
WACCN/A
ENSC Yearly LT Debt VS Equity VS FCFENSC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 2.42 indicates that ENSC has no problem at all paying its short term obligations.
ENSC has a worse Current ratio (2.42) than 70.77% of its industry peers.
A Quick Ratio of 2.42 indicates that ENSC has no problem at all paying its short term obligations.
With a Quick ratio value of 2.42, ENSC is not doing good in the industry: 69.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2.42
ENSC Yearly Current Assets VS Current LiabilitesENSC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ENSC have decreased strongly by -152.83% in the last year.
The Revenue has grown by 133.11% in the past year. This is a very strong growth!
Measured over the past years, ENSC shows a quite strong growth in Revenue. The Revenue has been growing by 13.86% on average per year.
EPS 1Y (TTM)-152.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-111.68%
Revenue 1Y (TTM)133.11%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%153.19%

3.2 Future

ENSC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 87.91% yearly.
The Revenue is expected to grow by 176.07% on average over the next years. This is a very strong growth
EPS Next Y25.67%
EPS Next 2Y87.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y210.46%
Revenue Next 3Y176.07%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ENSC Yearly Revenue VS EstimatesENSC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2026 2027 20M 40M 60M 80M
ENSC Yearly EPS VS EstimatesENSC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -1K -2K -3K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ENSC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ENSC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENSC Price Earnings VS Forward Price EarningsENSC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENSC Per share dataENSC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as ENSC's earnings are expected to grow with 87.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y87.91%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ENSC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENSYSCE BIOSCIENCES INC

NASDAQ:ENSC (4/24/2025, 3:21:44 PM)

3.1201

-0.55 (-14.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10 2025-03-10/amc
Earnings (Next)05-12 2025-05-12
Inst Owners15.34%
Inst Owner Change0%
Ins Owners1.17%
Ins Owner Change0%
Market Cap5.12M
Analysts82.86
Price Target47.66 (1427.52%)
Short Float %3.21%
Short Ratio1.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)59.65%
Min EPS beat(2)-3.95%
Max EPS beat(2)123.26%
EPS beat(4)3
Avg EPS beat(4)51.02%
Min EPS beat(4)-3.95%
Max EPS beat(4)123.26%
EPS beat(8)6
Avg EPS beat(8)36.7%
EPS beat(12)9
Avg EPS beat(12)36.15%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)826.08%
Min Revenue beat(2)411.37%
Max Revenue beat(2)1240.78%
Revenue beat(4)2
Avg Revenue beat(4)396.63%
Min Revenue beat(4)-40.59%
Max Revenue beat(4)1240.78%
Revenue beat(8)3
Avg Revenue beat(8)190.74%
Revenue beat(12)3
Avg Revenue beat(12)109.5%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-54.19%
EPS NQ rev (1m)10.67%
EPS NQ rev (3m)-1407.5%
EPS NY rev (1m)23.53%
EPS NY rev (3m)23.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.98
P/FCF N/A
P/OCF N/A
P/B 1.38
P/tB 1.38
EV/EBITDA N/A
EPS(TTM)-13.4
EYN/A
EPS(NY)-9.96
Fwd EYN/A
FCF(TTM)-4.57
FCFYN/A
OCF(TTM)-4.57
OCFYN/A
SpS3.18
BVpS2.26
TBVpS2.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -142.7%
ROE -215.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.42
Quick Ratio 2.42
Altman-Z -32.85
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-152.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-111.68%
EPS Next Y25.67%
EPS Next 2Y87.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)133.11%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%153.19%
Revenue Next Year-100%
Revenue Next 2Y210.46%
Revenue Next 3Y176.07%
Revenue Next 5YN/A
EBIT growth 1Y37.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-209.36%
EBIT Next 3Y51.15%
EBIT Next 5YN/A
FCF growth 1Y30.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.4%
OCF growth 3YN/A
OCF growth 5YN/A